Dapagliflozin improves erectile dysfunction in patients with type 2 diabetes mellitus: an open-label, non-randomized pilot study.

Rossella CannarellaRosita A CondorelliClaudia LeanzaVincenzo GarofaloAntonio AversaGiuseppe PapaAldo E CalogeroSandro La Vignera

Published in: Diabetic medicine : a journal of the British Diabetic Association (2023)

Dapagliflozin improves ED in patients with T2DM and enhances the efficacy of tadalafil. Further studies are needed to confirm our results explain the mechanism(s) by which dapagliflozin exerts its effects on ED.

Keyphrases

emergency department
double blind
open label
placebo controlled
phase iii
clinical trial
phase ii
type diabetes
case control
benign prostatic hyperplasia
adipose tissue
glycemic control
insulin resistance